AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
ANI Pharmaceuticals Inc. Surpasses Analyst Target Price of $83.12
ByAinvest
Tuesday, Aug 12, 2025 10:24 am ET1min read
ANI Pharmaceuticals Inc (ANIP) shares have crossed above the average analyst 12-month target price of $83.12, trading at $84.88/share. The average analyst target is based on 8 different analyst targets, ranging from $65 to $94. Investors should assess the company and decide whether the valuation has gotten stretched or if there is room for further growth.
ANI Pharmaceuticals Inc (ANIP) shares have surged above the average analyst 12-month target price of $83.12, trading at $84.88 per share. The average target is based on eight different analyst estimates, ranging from $65 to $94 [1][2].The recent price surge follows the company's strong second-quarter 2025 results. ANI Pharmaceuticals reported an adjusted earnings per share (EPS) of $1.80, surpassing the FactSet consensus estimate of $1.41. Revenue also exceeded expectations, reaching $211.4 million compared to the forecast of $187.34 million [1][2].
A significant contributor to the strong financial performance was Cortrophin Gel, which generated $81.6 million in revenue, marking a 66% year-over-year increase and a 54% sequential rise from Q1 2025. The company has raised its guidance for Cortrophin Gel to between $322 million and $329 million for 2025 [2].
Analysts have responded to these results with increased price targets. Truist Securities raised its price target to $77.00 from $65.00, maintaining a Hold rating, while H.C. Wainwright increased its target to $93.00 from $84.00, maintaining a Buy rating [1][2].
Investors should assess ANI Pharmaceuticals' valuation and decide whether the stock has become overvalued or if there is room for further growth. The company's strong performance and positive outlook from analysts suggest continued growth potential.
References:
[1] https://www.investing.com/news/analyst-ratings/ani-pharmaceuticals-stock-price-target-raised-to-77-from-65-at-truist-securities-93CH-4183314
[2] https://www.investing.com/news/analyst-ratings/ani-pharmaceuticals-stock-price-target-raised-to-93-from-84-at-hc-wainwright-93CH-4182592
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet